We are live on ! Find out more
FCMI

Foresite Capital Management IV Portfolio holdings

AUM $237M
1-Year Est. Return 107.53%
This Fund
S&P 500
This Quarter Est. Return
-15.5%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$149M
AUM Growth
-$49.1M
Cap. Flow
-$20.5M
Cap. Flow %
-13.8%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
1
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
PHVS icon
Pharvaris
PHVS
+$5.19M

Top Sells

Rank Stock Value
1
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHVS icon
1
Pharvaris
PHVS
$2.28B
$80.7M 54.23%
4,293,854
+255,012
+6% +$5.19M
KURA icon
2
Kura Oncology
KURA
$800M
$38.1M 25.59%
1,849,947
– –
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.69B
$18M 12.07%
875,000
– –
LYEL icon
4
Lyell Immunopharma
LYEL
$317M
$12.1M 8.11%
416,250
– –
KNTE
5
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
– –
-9,671,643
Closed -$25.7M

Similar funds

BCM
Birmingham Capital Management Birmingham, Alabama $237M AUM 32.7% 1-Year Est. Return
AG
ASO Group Road Town $237M AUM
FL
FreeGulliver LLC New Orleans, Louisiana $237M AUM 21.92% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
MFA
Millington Financial Advisors Naperville, Illinois $237M AUM 22.22% 1-Year Est. Return
TCM
Tekne Capital Management New York $237M AUM 62.98% 1-Year Est. Return
WW
Windle Wealth Oklahoma City, Oklahoma $237M AUM 22.79% 1-Year Est. Return
CB
CNB Bank Clearfield, Pennsylvania $238M AUM 26.55% 1-Year Est. Return

Foresite Capital Management IV's Q2 2024 Portfolio in Review

As of Q2 2024, Foresite Capital Management IV held 5 positions worth $149M, down 25% from $198M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management IV withdrew a net $20.5M in Q2 2024, closing 1 position. Its most notable exit was Kinnate Biopharma Inc. Common Stock, an estimated $25.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Foresite Capital Management IV added an estimated $5.19M to Pharvaris.

  • Foresite Capital Management IV added most to Pharvaris in Q2 2024, an estimated $5.19M increase.
  • Foresite Capital Management IV fully exited Kinnate Biopharma Inc. Common Stock in Q2 2024, selling an estimated $25.7M.
  • Foresite Capital Management IV's ten largest holdings make up 100% of its $149M portfolio in Q2 2024.
  • Foresite Capital Management IV opened 0 new positions and closed 1 in Q2 2024.
  • Foresite Capital Management IV's portfolio value fell 25% quarter-over-quarter to $149M.

Based on Foresite Capital Management IV's 13F filing for Q2 2024, filed 13 Aug 2024.